news, journals and articles from all over the world.
Preclinical results for a COVID-19 vaccine candidate appear to distinguish this vaccine candidate from other vaccine candidates. A single nasal dose in mice gave a potent T-cell response at the lung mucus layer, including killer CD8+ T-cells that can recognize and kill virally infected cells.
Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus. The investigators next plan to test the vaccine in nonhuman primates and humans to see if it is safe and effective in preventing COVID-19 infection.
Many viruses mutate so quickly that identifying vaccines or treatments is like trying to hit a moving target. Now, scientists report a new technique that can detect minor changes in RNA sequences. They present their results today at the American Chemical Society Fall 2020 Virtual Meeting & Expo.
Keck Medicine of USC launches phase 3 trial for COVID-19 vaccine. To ensure access for underrepresented and vulnerable populations, researchers are setting up a satellite location in the meat-packing community of Vernon, CA.
PDS Biotechnology, a clinical stage immunotherapy company, has announced positive results from preclinical testing conducted at the University of Kentucky College of Medicine of its COVID-19 vaccine candidate, PDS0203.
Researchers at Washington University School of Medicine in St. Louis have created a COVID-19 vaccine candidate from a replicating virus. This experimental vaccine has proven effective at preventing pneumonia in mice.
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.
A new study at the University of Chicago and Duke University finds that a new type of intranasal vaccine induces a strong immune response in lungs, with possible implications for COVID-19. The system uses nanofibers tagged with antigens to prime the immune system against a potential invasion.
When a COVID-19 vaccine becomes available, 66 percent of adults are likely to get vaccinated, and have their children vaccinated as well, according to a new nationwide survey led by researchers from Rutgers University–New Brunswick, Northeastern, Harvard, and Northwestern universities.
Summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.
Immunization programs offered in low- and middle-income countries provide a high “return on investment” in terms of the economic costs of diseases that are prevented and the values of lives that would have been lost.
A leading COVID-19 vaccine candidate developed at Beth Israel Deaconess Medical Center creates the groundwork for a newly launched COVID-19 vaccine clinical trial
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
Recent animal experiments showed that LEAPS COVID 19 conjugates induced faster and much higher than expected antibody responses against a non-mutating region of the virus that causes COVID 19, after only one injection.
A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 — the virus that causes the disease — drop sharply over the first three months after infection, decreasing by roughly half every 73 days. If sustained at that rate, the antibodies would disappear within about a year.
Researchers at The Rockefeller University in New York have developed new tools to rapidly test the ability of antibodies to neutralize SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic. The approach, described today in the Journal of Experimental Medicine (JEM), will help researchers understand whether patients are susceptible to reinfection by SARS-CoV-2 and assess the effectiveness of experimental vaccines, as well as develop antibody-based therapies against the disease.
The University of Miami Miller School of Medicine has been selected to be part of the National Institutes of Health COVID-19 Prevention Trials Network (CoVPN) to launch clinical trials to test investigational COVID-19 vaccines.
From mRNA vaccines entering clinical trials, to peptide-based vaccines and using molecular farming to scale vaccine production, the COVID-19 pandemic is pushing new and emerging nanotechnologies into the frontlines and the headlines.
Nanoengineers at UC San Diego detail the current approaches to COVID-19 vaccine development, and highlight how nanotechnology has enabled these advances, in a review article in Nature Nanotechnology published July 15.
Fueling transformative research through collaboration, the San Antonio Partnership for Precision Therapeutics (SAPPT) announces the funding of three more collaborative COVID-19 research efforts in San Antonio. SAPPT has awarded more than $600,000 to fund these projects, following the funding of a SARS CoV-2 vaccine project announced in April of this year.
University of Wisconsin–Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination — including a COVID-19 vaccine from Moderna Therapeutics that has advanced to clinical trials with humans.
Article title: Experimental analysis of T cell epitopes for designing liver cancer vaccine predicted by system-level immunoinformatics approach Authors: Syed Aun Muhammad, Sidra Zafar, Samana Zahra Rizvi, Imran Imran, Fahad Munir, Muhammad Babar Jamshed, Amjad Ali, Xiaogang Wu, Numan Shahid,…
Experiments in mice have shown early success in vaccinating them against potentially deadly bacterial infections, such as methicillin-resistant Staphylococcal aureus, or MRSA, the strain resistant to most drug treatments.
Saint Louis University researcher Daniel Hoft, M.D., Ph.D., has been named to the National Vaccine Advisory Committee. Hoft was named a voting member of the group on June 8.
The University of Illinois at Chicago will soon test a vaccine for COVID-19. Expected to launch July 9, the trial — a phase 3 clinical study — will test the efficacy of a vaccine developed by biotech company Moderna.
In a new study, Johns Hopkins researchers found that testing people for SARS-CoV-2 — the virus that causes COVID-19 — too early in the course of infection is likely to result in a false negative test, even though they may eventually test positive for the virus.
Cancer researchers at Children’s Hospital of Philadelphia (CHOP) have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus. Using this strategy, the researchers believe a resulting vaccine would provide protection across the human population and drive a long-term immune response.
In a new study, published June 5, 2020, in the Journal of Experimental Medicine, scientists at La Jolla Institute for Immunology (LJI) shows that antibodies against JEV are “cross-reactive” and can also recognize Zika virus. Unfortunately, these antibodies can actually make Zika cases more severe.
A monthly media tip sheet of recent Fred Hutch research findings and other news.
A $1M gift from the John and Mary Tu Foundation is accelerating the efforts of UC San Diego translational research virologist Davey Smith to increase the number of people tested for COVID-19, as well as develop new ways to track and treat the virus. Smith and his team are studying how the disease spreads to better inform contact tracing, as well as leading clinical trials to test new drugs for treatment of COVID-19.
Notre Dame researchers create online tool to track development of coronavirus vaccines.
The internationally-renowned Gene Therapy Program at the University of Pennsylvania is joining the AAVCOVID vaccine program led by Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham. AAVCOVID is a unique gene-based vaccine candidate designed to protect against SARS-CoV-2, the virus that causes COVID-19.
Researchers have received funding from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to screen and evaluate certain molecules known as adjuvants that may improve the ability of coronavirus vaccines to stimulate the immune system and generate appropriate responses necessary to protect the general population against the virus.
Dan Barouch, MD, PhD (Center for Virology and Vaccine Research, BIDMC) and colleagues reported today in Science two studies of laboratory monkeys that suggest antibodies produced during recovery from COVID-19 provide immunity from the virus, whether triggered by infection or vaccine.
To help accelerate discovery of therapeutic antibodies or antiviral drugs for SARS-CoV-2, the virus that causes COVID-19, Lawrence Livermore National Laboratory has launched a searchable data portal to share its COVID-19 research with scientists worldwide and the general public.
David Peabody, PhD, and Bryce Chackerian, PhD, are creating vaccines from particles that are the opposite of Trojan Horses: they look deadly on the outside but are harmless on the inside. Their virus-like particles may rouse the immune system into combatting COVID-19. The idea is to trick the body into believing it’s been infected with a microscopic foe.
Two LLNL biomedical scientists who have worked for more than eight years to develop a tularemia vaccine are part of a three-institution team that has been funded to bring their candidate vaccine to readiness for use
Medicine’s great triumph over polio holds out hope we can do the same for COVID-19, two researchers say.
Communities on Facebook that distrust establishment health guidance are more effective than government health agencies and other reliable health groups at reaching and engaging “undecided” individuals, according to a study published today in the journal Nature.
FACULTY Q&AANN ARBOR–In late April, the federal government announced Operation Warp Speed, an aggressive COVID-19 vaccine development program that aims to have at least 300 million doses of vaccine available in the United States by January. Jason Pogue, clinical professor of pharmacy, discusses the feasibility of this aggressive timetable.
Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham, today announced progress towards the testing and development of an experimental vaccine called AAVCOVID, a novel gene-based vaccine candidate against SARS-CoV2, the virus that causes COVID-19. The AAVCOVID Vaccine Program is a unique, gene-based vaccine strategy that uses adeno-associated viral (AAV) vector, a clinically established gene transfer technology leveraging the properties of a harmless viral carrier.
Following the recent Coronavirus outbreak, almost three million people have been infected worldwide, whereas the death toll has already passed the 200,000 mark, according to official reports.
UNIVERSITY PARK, Pa. — Researchers are proposing a possible COVID-19 vaccine that could be good news for resisting current and future pandemics, as well as for the needle-phobic: inhalable vaccines. Scott Medina, Penn State assistant professor of biomedical engineering, is…
A new study by epidemiologists at the University of Notre Dame suggests social distancing measures at current levels in many states may need to be maintained until the summer to avoid a potentially deadly resurgence of the coronavirus.
UC San Diego nanoengineers received a Rapid Response Research (RAPID) grant from the National Science Foundation to develop—using a plant virus—a stable, easy to manufacture COVID-19 vaccine patch that can be shipped around the world and painlessly self-administered by patients.
To assist in the COVID-19 research effort, Lawrence Livermore National Laboratory, Penguin Computing and AMD have reached an agreement to upgrade the Lab’s unclassified, Penguin Computing-built Corona high performance computing (HPC) cluster with an in-kind contribution of cutting-edge AMD Instinct™ accelerators, expected to nearly double the peak performance of the machine.
The Weizmann Institute’s Prof. Roy Bar-Ziv has demonstrated the self-synthesis and self-assembly of a ribosomal subunit on the surface of a chip. The breakthrough could lead to novel types of vaccines, including for antibiotic-resistant bacteria, or to assembly lines to produce complex molecules for a range of industries.
Physicians and scientists at UC San Diego Health have launched a pair of serological tests that will look for novel coronavirus antibodies—evidence in persons tested that they have previously been infected by the viral cause of COVID-19, even if they never experienced tell-tale symptoms.
Supriya Munshaw, a senior lecturer at Johns Hopkins Carey Business School, offers insights on the likely time frame for a coronavirus vaccine, the steps involved in developing one, the most promising candidates currently in the labs of biotech companies, and why, years after the MERS and SARS outbreaks, a coronavirus vaccine still has not been produced.
In the race to identify solutions to the COVID-19 pandemic, researchers at the Department of Energy’s Oak Ridge National Laboratory are joining the fight by applying expertise in computational science, advanced manufacturing, data science and neutron science.
At Oak Ridge National Laboratory, it’s all-hands-on-deck for the world-leading experts in neutron scattering as they enter the fight against COVID-19. Researchers at the lab’s Spallation Neutron Source and High Flux Isotope Reactor have a plan of attack to unleash a full barrage of neutron capabilities in an ambitious set of experiments that will provide critical pieces of information about the virus’s biological structure and how it behaves.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu